Full-Time

Senior Scientist

Computational Chemistry

General Proximity

General Proximity

11-50 employees

Seed-stage platform for induced proximity drugs

No salary listed

San Francisco, CA, USA

In Person

On-site in San Francisco, CA; not remote; located at MBC BioLabs.

PhD

Category
Biology & Biotech (1)
Required Skills
Python
Machine Learning
Medicinal Chemistry

Get referred to General Proximity

See people who can refer or advise you

Requirements
  • PhD in Computational Chemistry, Medicinal Chemistry, Chemical Physics, Biophysics, Cheminformatics, Physical Organic Chemistry, or a related discipline
  • A minimum of 3 years of relevant experience in pharma, biotech, or a drug discovery-focused research environment
  • Track record of using computational chemistry to impact small-molecule drug discovery programs, ideally through hit-to-lead or lead optimization
  • Hands-on expertise in structure-based drug design, ligand-based design, docking, molecular dynamics, virtual screening, QSAR, scaffold hopping, virtual screening, FEP/free-energy methods, pharmacophore modeling, and multi-parameter optimization
  • Strong working knowledge of medicinal chemistry principles, SAR interpretation, physicochemical property optimization, ADME/PK concepts, developability considerations
  • Practical experience with cheminformatics platforms, chemical databases, chemical data curation, compound registration systems, and project-facing visualization tools
  • Experience with AI/ML applications in molecular design, including predictive modeling, generative chemistry, active learning, or AI-enabled compound prioritization
  • Strong programming or scripting ability, preferably Python, with experience using RDKit and modern data science workflows
  • Ability to communicate complex computational concepts clearly to medicinal chemists, biologists, and non-specialist stakeholders
  • Ability to collaborate within cross-functional teams and influence project decisions through strong scientific input
Responsibilities
  • Provide hands-on computational chemistry support to small-molecule discovery programs from target evaluation, hit identification, hit-to-lead, and lead optimization through candidate nomination
  • Apply structure-based and ligand-based design approaches to guide compound design, including docking, molecular dynamics, pharmacophore modeling, QSAR, scaffold hopping, virtual screening, FEP/free-energy methods, and multi-parameter optimization
  • Use structural biology data, including X-ray structures, cryo-EM structures, homology models, and AlphaFold-derived models, to generate actionable design hypotheses
  • Partner with the medicinal chemistry team to interpret SAR, optimize potency, selectivity, physicochemical properties, ADME/PK, developability, and synthetic feasibility
  • Contribute to computational design discussions with project teams and translate complex modeling results into clear, practical medicinal chemistry recommendations
  • Support portfolio prioritization by evaluating target tractability, ligandability, binding-site quality, chemical matter, and developability risks
  • Use and help improve chem and bioinformatics tools that support compound registration, structure-searching, SAR analysis, property visualization, compound triage, library design, and project decision-making
  • Apply tools for chemical data handling, including similarity and substructure searching, R-group analysis, matched molecular pairs, reaction enumeration, compound clustering, property prediction, and visualization
  • Work with internal or external engineering and data science teams to integrate chemical, biological, DMPK, structural, and assay data into usable project dashboards and design tools
  • Follow best practices for chemical data quality, assay data curation, compound annotation, metadata standards, and reproducible computational workflows
  • Use commercial and open-source computational tools, including platforms such as Schrödinger, MOE, CCDC tools, ChemAxon, KNIME, Pipeline Pilot, RDKit, DataWarrior, Spotfire, and related systems
  • Apply user-friendly AI/ML-enabled molecular design tools, including generative chemistry, predictive ADME/Tox models, property prediction, active learning, virtual screening, and decision-support systems
  • Help incorporate AI tools into the DMTA cycle, including compound prioritization, library design, synthetic route ideation, molecular-property prediction, and design hypothesis generation
  • Support AI literacy across chemistry and project teams by helping colleagues understand appropriate use, limitations, and interpretation of predictive models
  • Help develop workflows that allow medicinal chemists to use modeling and AI tools without requiring deep computational expertise
  • Contribute to the computational chemistry approach for projects and align it with discovery program needs
  • Serve as a subject-matter resource for computational chemistry, cheminformatics, AI-enabled design, and molecular modeling
  • Support collaborations with CROs, software vendors, academic groups, and computational chemistry consultants where appropriate
  • Represent computational chemistry in project team meetings and program discussions
  • Maintain awareness of emerging computational, AI, and cheminformatics technologies and recommend adoption where scientifically and operationally justified
Desired Qualifications
  • Experience working in a biotech or fast-moving discovery organization
  • Experience implementing user-friendly modeling tools for medicinal chemists
  • Familiarity with cloud-based or high-performance computing environments
  • Experience with automated DMTA workflows, electronic lab notebooks, compound management systems, assay-data systems, and integrated discovery platforms
  • Experience supporting discovery across multiple modalities, such as covalent inhibitors, bifunctional molecules, and molecular glues
  • Familiarity with synthetic accessibility prediction, retrosynthesis tools, reaction enumeration, and library design
  • Scientific contributions through publications, presentations, patents, open-source contributions, or demonstrated project impact

Preparing a concise company summary based on provided description.

Company Size

11-50

Company Stage

Seed

Total Funding

$16.1M

Headquarters

San Francisco, California

Founded

2019

Get referred to General Proximity

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FreeMind and Daewoong invested on May 4, 2026, adding strategic Asian commercial reach.
  • ARPA-H and NCI grants de-risk non-dilutive financing for 2026 preclinical work.
  • General Proximity raised $28 million total and expanded July 2026 hiring momentum.

What critics are saying

  • General Proximity still has no public IND or named clinical asset as of July 2026.
  • Platform biology remains unproven clinically; Daiichi Sankyo and Daewoong can walk away.
  • Larger rivals like Revolution Medicines, Nurix, and C4 Therapeutics crowd induced-proximity oncology.

What makes General Proximity unique

  • OmniTAC scans effectors broadly, not one degradation pathway, widening target access.
  • Daiichi Sankyo signed a multi-target oncology collaboration on November 12, 2025.
  • General Proximity says its lead program is internally discovered and best-in-class.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

401(k) Company Match

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

15%
Noah Business Intelligence
Jul 6th, 2026
General Proximity Bio raises $28M across seed and pre-Series A for induced-proximity drug platform

San Francisco biotech General Proximity Bio has secured notable early-stage investment for its induced-proximity medicine platform. The company emerged from stealth in January 2025 with $16 million in seed funding led by Felicis Ventures, alongside Y Combinator, age1, and other investors. It subsequently closed an oversubscribed $12 million pre-Series A round, attracting strategic investment from Daewoong Pharmaceutical and FreeMind Investments. General Proximity also received non-dilutive support through grants from ARPA-H and the National Cancer Institute. The platform targets proteins traditionally considered difficult to drug, focusing on cancer, cardiometabolic disease, neurodegeneration, and longevity. The company remains preclinical with no public IND filing or lead asset. Scientific challenges in proximity-based drug design include selectivity, pharmacokinetics, oral delivery, and off-target effects. General Proximity is pursuing a platform approach rather than developing a single near-term product.

Yonhap Infomax
Apr 30th, 2026
Daewoong Pharmaceutical invests in US biotech General Proximity for induced proximity drug development

Daewoong Pharmaceutical has invested in US biotech firm General Proximity alongside venture capital fund Freemind Investment to collaborate on new drug development. The investment amount was not disclosed. The partnership aims to secure "induced proximity" technology, a next-generation drug development method that regulates protein function by bringing disease-related proteins and regulatory proteins together. This approach differs from conventional methods that required drugs to fit precisely into specific binding sites, potentially expanding treatment options for previously inaccessible proteins. Founded in 2019, General Proximity possesses a platform for discovering induced proximity therapeutics based on Effectome scanning technology. The company is developing new drug pipelines in oncology, cardiovascular and metabolic diseases, and neurodegenerative diseases.

Business News Today
Nov 12th, 2025
General Proximity inks Daiichi Sankyo deal to push precision small molecules into oncology

General Proximity inks Daiichi Sankyo deal to push precision small molecules into oncology. General Proximity partners with Daiichi Sankyo to develop proximity-based cancer drugs using OmniTAC. Discover how this biotech is redefining drug discovery. General Proximity, a San Francisco-based biotechnology company developing proximity-induced medicines, has signed a strategic multi-target collaboration with Daiichi Sankyo Co., Ltd. to co-develop cancer treatments using its proprietary OmniTAC discovery platform. The partnership, routed through the Daiichi Sankyo Research Institute in Boston, will focus on identifying first-in-class therapeutic candidates capable of modulating proteins traditionally viewed as "undruggable" in oncology.

VCNewsDaily
Jan 3rd, 2025
General Proximity Raises $16M Funding

General Proximity, a biotech platform company, has emerged from stealth with $16M in funding. The oversubscribed seed round was led by Aydin Senkut of Felicis, with participation from Y Combinator, age1, Modi Ventures, Wilson Sonsini, and angel investors like Jeff Dean and Ben Mann. The funds will accelerate the development of treatments targeting undruggable proteins related to cancer, cardiometabolic disease, neurodegeneration, and longevity.

PR Newswire
Jan 3rd, 2025
General Proximity Raises $16M for Undruggable Targets

General Proximity has emerged from stealth with $16M to develop treatments for undruggable proteins linked to cancer, cardiometabolic disease, neurodegeneration, and longevity using its OmniTAC platform. The $8M seed round was led by Aydin Senkut at Felicis. Other investors include Y Combinator and Jim Dahl. The company aims to revolutionize drug discovery with a potential market exceeding $250 billion annually.